BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

...steps by Gilead Sciences Inc. could include testing the compound in animal models of HCV. ContraVir Pharmaceuticals...
BioCentury | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

...Pharmaceuticals Inc. (NASDAQ:DFFN) named William Hornung CBO, a newly created position. He was CFO at ContraVir Pharmaceuticals...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

...they want to build. For instance, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), ContraVir Pharmaceuticals...
...I/II) 1 Altimmune Inc. (NASDAQ:ALT) CD4 and CD8 T cell booster HepTcell (Ph I) 1 ContraVir Pharmaceuticals...
...functional cure of hepatitis B.” Clinical Liver Disease (2016) Erin McCallister, Senior Editor Arbutus Biopharma Corp. Assembly Biosciences Inc. Hepion Pharmaceuticals Inc. Gilead...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...4/28/17 $15.0 $73.7 $95.8 30% Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) 4/27/17 $87.8 $177.0 $152.9 -14% ContraVir Pharmaceuticals...
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

...the product from Chimerix (see BioCentury, Dec. 22, 2014 ). Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals...
...Endpoint: Safety and antiviral activity; pharmacokinetics Status: Interim Phase IIa data Milestone: NA Jaime De Leon TXL Chimerix Inc. Hepion Pharmaceuticals Inc. Viral...
BioCentury | Apr 27, 2017
Financial News

ContraVir completes follow-on

...Infectious disease company ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) raised $12 million on April 25 through the sale of...
...in a follow-on underwritten by Canaccord Genuity and Maxim. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Mary Romeo Hepion Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

...vehicle. Next steps could include identifying and testing additional CYPA inhibitors in models of ALS. ContraVir Pharmaceuticals...
BioCentury | Dec 1, 2016
Product R&D

De-stressing about NASH

...have primarily pursued cyclophilin inhibition for anti-infectives, in addition to immunosuppression with ciclosporin. These include ContraVir Pharmaceuticals...
...NVP015 in 2018 or 2019. Companies and Institutions Mentioned Arbutus Biopharma Corp. (NASDAQ:ABUS), Burnaby, B.C. ContraVir Pharmaceuticals...
BioCentury | Oct 24, 2016
Clinical News

CMX157: Phase I/IIa ongoing

...rights to CMX157 from Chimerix (see BioCentury, Dec. 22, 2014). Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals...
BioCentury | Jun 27, 2016
Company News

Ciclofilin, ContraVir Pharmaceuticals deal

...analog tenofovir, from Chimerix Inc. (NASDAQ:CMRX, Durham, N.C.). Ciclofilin Pharmaceuticals Inc. , San Diego, Calif. ContraVir Pharmaceuticals...
Items per page:
1 - 10 of 27
BioCentury | Aug 16, 2018
Distillery Therapeutics

Infectious disease

...steps by Gilead Sciences Inc. could include testing the compound in animal models of HCV. ContraVir Pharmaceuticals...
BioCentury | Sep 1, 2017
Company News

Management tracks: BioDelivery, Almirall, Nabriva

...Pharmaceuticals Inc. (NASDAQ:DFFN) named William Hornung CBO, a newly created position. He was CFO at ContraVir Pharmaceuticals...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

...they want to build. For instance, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), ContraVir Pharmaceuticals...
...I/II) 1 Altimmune Inc. (NASDAQ:ALT) CD4 and CD8 T cell booster HepTcell (Ph I) 1 ContraVir Pharmaceuticals...
...functional cure of hepatitis B.” Clinical Liver Disease (2016) Erin McCallister, Senior Editor Arbutus Biopharma Corp. Assembly Biosciences Inc. Hepion Pharmaceuticals Inc. Gilead...
BioCentury | Jul 7, 2017
Finance

Generalists needed

...4/28/17 $15.0 $73.7 $95.8 30% Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) 4/27/17 $87.8 $177.0 $152.9 -14% ContraVir Pharmaceuticals...
BioCentury | Apr 28, 2017
Clinical News

Tenofovir exalidex: Interim Ph IIa data

...the product from Chimerix (see BioCentury, Dec. 22, 2014 ). Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals...
...Endpoint: Safety and antiviral activity; pharmacokinetics Status: Interim Phase IIa data Milestone: NA Jaime De Leon TXL Chimerix Inc. Hepion Pharmaceuticals Inc. Viral...
BioCentury | Apr 27, 2017
Financial News

ContraVir completes follow-on

...Infectious disease company ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV) raised $12 million on April 25 through the sale of...
...in a follow-on underwritten by Canaccord Genuity and Maxim. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Mary Romeo Hepion Pharmaceuticals Inc....
BioCentury | Feb 15, 2017
Distillery Therapeutics

Neurology

...vehicle. Next steps could include identifying and testing additional CYPA inhibitors in models of ALS. ContraVir Pharmaceuticals...
BioCentury | Dec 1, 2016
Product R&D

De-stressing about NASH

...have primarily pursued cyclophilin inhibition for anti-infectives, in addition to immunosuppression with ciclosporin. These include ContraVir Pharmaceuticals...
...NVP015 in 2018 or 2019. Companies and Institutions Mentioned Arbutus Biopharma Corp. (NASDAQ:ABUS), Burnaby, B.C. ContraVir Pharmaceuticals...
BioCentury | Oct 24, 2016
Clinical News

CMX157: Phase I/IIa ongoing

...rights to CMX157 from Chimerix (see BioCentury, Dec. 22, 2014). Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. ContraVir Pharmaceuticals...
BioCentury | Jun 27, 2016
Company News

Ciclofilin, ContraVir Pharmaceuticals deal

...analog tenofovir, from Chimerix Inc. (NASDAQ:CMRX, Durham, N.C.). Ciclofilin Pharmaceuticals Inc. , San Diego, Calif. ContraVir Pharmaceuticals...
Items per page:
1 - 10 of 27